| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA0909169 |
| P698 | PubMed publication ID | 20647198 |
| P50 | author | Raashid Ahmed Luqmani | Q38322152 |
| Jan Willem Cohen Tervaert | Q60901166 | ||
| Vladimír Tesař | Q69807487 | ||
| P2093 | author name string | Michael Walsh | |
| Thomas Hauser | |||
| Caroline O Savage | |||
| Mårten Segelmark | |||
| David R W Jayne | |||
| European Vasculitis Study Group | |||
| Kerstin Westman | |||
| Matthew D Morgan | |||
| Pieter van Paassen | |||
| Chen Au Peh | |||
| Rachel B Jones | |||
| Dorothy Walsh | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| P304 | page(s) | 211-220 | |
| P577 | publication date | 2010-07-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis | |
| P478 | volume | 363 |
| Q92884290 | A Case of ANCA-Associated Vasculitis |
| Q36661237 | A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis |
| Q35226275 | A case of granulomatosis with polyangiitis preceded by subacute thyroiditis |
| Q40169983 | A case of refractory polyarteritis nodosa successfully treated with rituximab |
| Q58377805 | A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis |
| Q88851412 | ANCA Glomerulonephritis and Vasculitis |
| Q44868649 | ANCA comes of age-but with caveats |
| Q35678050 | ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study |
| Q39210329 | ANCA-Associated Vasculitis Pathogenesis: A Commentary |
| Q37798163 | ANCA-associated vasculitides--advances in pathogenesis and treatment |
| Q98778531 | ANCA-associated vasculitis |
| Q33644574 | ANCA-associated vasculitis in childhood: recent advances. |
| Q39339897 | ANCA-associated vasculitis with renal involvement |
| Q39114014 | ANCA-associated vasculitis. |
| Q39673095 | ANCA-associated vasculitis: a comparison of cases presenting to nephrology and rheumatology services |
| Q36949060 | Acute Respiratory Distress Syndrome and Posterior Reversible Encephalopathy Syndrome following Rituximab Therapy |
| Q38034940 | Advances in therapy for ANCA-associated vasculitis |
| Q36134791 | Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function |
| Q53452166 | An Elderly Man with Fatigue, Dyspnea, and Kidney Failure. |
| Q57453127 | Anti-neutrophil cytoplasmic antibody-associated hypertrophic cranial pachymeningitis and otitis media: a review of literature |
| Q49691317 | Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes |
| Q38082991 | Antineutrophil cytoplasm antibody-associated vasculitis: recent developments |
| Q55340553 | Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. |
| Q38100780 | Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? |
| Q59813121 | Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment |
| Q92875697 | Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
| Q35992340 | Atypical Endobronchial Carcinoid with Postobstructive Pneumonia Obscuring the Diagnosis of Granulomatosis with Polyangiitis |
| Q47105115 | Avoidance of Harm From Treatment for ANCA-Associated Vasculitis |
| Q38189360 | B cell depletion: rituximab in glomerular disease and transplantation |
| Q30252928 | B cells and atherosclerosis. |
| Q41730840 | B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis |
| Q38097162 | B-cell targeted therapeutics in clinical development |
| Q43687687 | B-cell targeted therapy for children and adolescents with rheumatic diseases |
| Q38371009 | B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis |
| Q38131034 | B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress |
| Q38159787 | B-cell-targeted therapy in adult glomerulonephritis |
| Q37820338 | Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach |
| Q35836369 | Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service |
| Q54878489 | Bilateral dacryoadenitis as initial presentation of a locally aggressive and unresponsive limited form of orbital granulomatosis with polyangiitis. |
| Q36934322 | Biologic agents in systemic vasculitis. |
| Q38514894 | Biologic agents in the treatment of glomerulonephritides |
| Q38831383 | Biological Therapy-Induced Systemic Vasculitis |
| Q38763327 | Biologics for the treatment of autoimmune renal diseases. |
| Q82340953 | Biotherapies to treat necrotizing vasculitis |
| Q52647071 | Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. |
| Q38647220 | Birmingham vasculitis activity score of more than 9.5 at diagnosis is an independent predictor of refractory disease in granulomatosis with polyangiitis. |
| Q42956266 | Boon and bane of remission induction with rituximab in ANCA-associated vasculitis: lessons learned from the RAVE-ITN follow-up study |
| Q39254767 | Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's). |
| Q36003085 | CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN. |
| Q37282164 | CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients |
| Q90703443 | Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis |
| Q38088389 | Case of acute, resistant fulminant Wegener's granulomatosis successfully treated by rituximab |
| Q57809484 | Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange |
| Q26824580 | Cellular targeting in autoimmunity |
| Q61449548 | Central Nervous System Involvement in ANCA-Associated Vasculitis: What Neurologists Need to Know |
| Q35151866 | Central nervous system vasculitis: still more questions than answers |
| Q51688522 | Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. |
| Q87393401 | Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis |
| Q35572715 | Chronic alveolar haemorrhage in a paediatric patient: a diagnostic and treatment challenge |
| Q41481664 | Clinical Trials in Vasculitis |
| Q40169677 | Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study |
| Q40570832 | Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception |
| Q33696589 | Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis) |
| Q51201612 | Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). |
| Q37006816 | Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type |
| Q39088103 | Clinical trials in antineutrophil cytoplasmic antibody-associated vasculitis: what we have learnt so far, and what we still have to learn |
| Q41563712 | Clinical trials. Rituximab for maintenance of remission in AAV. |
| Q39655488 | Clinicopathologic characteristics of Weneger's granulomatosis: A report of three cases |
| Q35927051 | Coexistence of ANCA-associated glomerulonephritis and anti-phospholipase A(2) receptor antibody-positive membranous nephropathy |
| Q48305722 | Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. |
| Q55191066 | Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. |
| Q35548589 | Combination therapy with rituximab and cyclophosphamide in the treatment of anti-neutrophil cytoplasmic antibodies (ANCA) positive pulmonary hemorrhage: case report |
| Q42086661 | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea |
| Q90451505 | Complications of Immunosuppression in Glomerular Disease |
| Q51593366 | Complications of long-term therapy for ANCA-associated systemic vasculitis. |
| Q41208157 | Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? |
| Q92151255 | Concurrent treatment with rituximab and plasma exchange for severe refractory granulomatosis with polyangiitis: A case report |
| Q28393792 | Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides |
| Q38543360 | Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients? |
| Q50700806 | Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial |
| Q34960458 | Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents |
| Q27025692 | Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis) |
| Q38088415 | Current modalities in the diagnosis of pulmonary vasculitis |
| Q35865798 | Current status of outcome measure development in vasculitis |
| Q35065425 | Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab |
| Q37859113 | Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis |
| Q38710150 | Cyclophosphamide in dermatology |
| Q40785035 | Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes |
| Q38043946 | Damage assessment in ANCA-associated vasculitis. |
| Q30696868 | Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. |
| Q40118140 | De Novo HHV-8 tumors induced by rituximab in autoimmune or inflammatory systemic diseases |
| Q36652772 | Decreased CD5⁺ B cells in active ANCA vasculitis and relapse after rituximab. |
| Q35426533 | Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire |
| Q38033433 | Diagnosis and management of pulmonary vasculitis |
| Q51561480 | Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes. |
| Q39530208 | Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). |
| Q38170477 | Does cyclophosphamide still have a role in the treatment of severe inflammatory eye disease? |
| Q35816996 | Drug-induced glomerular disease: immune-mediated injury |
| Q39037643 | Drug-induced nephropathies |
| Q40684657 | EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. |
| Q33418352 | Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura |
| Q93161825 | Effector and regulatory B cells in immune-mediated kidney disease |
| Q33757209 | Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series |
| Q38353577 | Efficacy and safety of rituximab in rheumatic diseases |
| Q64963768 | Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. |
| Q34037683 | Efficacy of remission-induction regimens for ANCA-associated vasculitis |
| Q40778053 | Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis |
| Q38161794 | Emerging cell and cytokine targets in rheumatoid arthritis |
| Q53513595 | End-stage renal disease in ANCA-associated vasculitis. |
| Q37149922 | Enho Mutations Causing Low Adropin: A Possible Pathomechanism of MPO-ANCA Associated Lung Injury |
| Q60907829 | Eosinophilia and Kidney Disease: More than Just an Incidental Finding? |
| Q52611171 | Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies. |
| Q92195595 | Eosinophilic Granulomatosis with Polyangiitis: Experiences in Korean Patients |
| Q55311740 | Eosinophils from Physiology to Disease: A Comprehensive Review. |
| Q44480906 | Established medications : new areas of application |
| Q64226538 | Estimating the Change in Renal Function During the First Year of Therapy in ANCA-Associated Vasculitis |
| Q89845421 | Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, |
| Q38126924 | Experience with low-dose rituximab in off-label indications at two tertiary hospitals |
| Q37640836 | Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis |
| Q35767500 | Extracorporeal membrane oxygenation for Life-threatening ANCA-positive pulmonary capillaritis. A review of UK experience. |
| Q35535231 | Fetal outcomes after rituximab exposure in women with autoimmune vasculitis |
| Q38334787 | Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis |
| Q40459136 | Genetic variants in ANCA-associated vasculitis: a meta-analysis. |
| Q28943363 | Genetically distinct subsets within ANCA-associated vasculitis |
| Q90923910 | Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. |
| Q38316279 | Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis |
| Q35946429 | Gleaning relapse risk from B cell phenotype: decreased CD5+ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. |
| Q40325057 | Glomerular Diseases and Renal Transplantation: Pathogenic Pathways and Evolution of Therapeutic Interventions |
| Q86521591 | Glomerular disease in 2014: advances in basic science and translational medicine |
| Q50513429 | Glomerulonephritis therapy: is there a role for green tea? |
| Q30849537 | Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials |
| Q26765803 | Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge |
| Q26748200 | Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations |
| Q36193516 | Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration |
| Q37979678 | Granulomatosis with polyangiitis in childhood |
| Q46055267 | HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study |
| Q93050598 | Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist |
| Q38155812 | Headaches related to rheumatologic disease |
| Q47552107 | Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure |
| Q38283472 | High-risk pregnancy and the rheumatologist. |
| Q38709517 | Hurdles to the introduction of new therapies for immune-mediated kidney diseases |
| Q26749168 | Hydralazine-induced pauci-immune glomerulonephritis: intriguing case series with misleading diagnoses |
| Q40075352 | Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q34201979 | Immunomodulation with eicosapentaenoic acid supports the treatment of autoimmune small-vessel vasculitis |
| Q90288544 | Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era? |
| Q34282077 | Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides |
| Q38152651 | Impact of rituximab trials on the treatment of ANCA-associated vasculitis |
| Q35212086 | Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies |
| Q37522782 | Improving outcomes in patients with lupus and end-stage renal disease |
| Q38413238 | Incidence of Malignancies in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Diagnosed Between 1991 and 2013. |
| Q38044851 | Indications for use and safety of rituximab in childhood renal diseases |
| Q37302171 | Induction treatment of previously undiagnosed ANCA-associated vasculitis in a renal transplant patient with Rituximab |
| Q40075357 | Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease |
| Q40065728 | Infectious complications of rituximab therapy in renal disease. |
| Q50206075 | Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis |
| Q24187038 | Interventions for renal vasculitis in adults |
| Q34377832 | Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum. |
| Q36583330 | Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis |
| Q51834131 | Investigational drugs in systemic vasculitis. |
| Q34124711 | Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis |
| Q48937679 | Issues in trial design for ANCA-associated and large-vessel vasculitis |
| Q26775756 | Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications |
| Q34298085 | Kidney biopsy in patients with glomerulonephritis: is the earlier the better? |
| Q38367357 | Large-vessel involvement in granulomatosis with polyangiitis successfully treated with rituximab: A case report and literature review |
| Q45138053 | Late recovery of renal function by rituximab in a patient with Wegener's granulomatosis. |
| Q38193735 | Late-onset neutropenia following rituximab treatment for rheumatologic conditions |
| Q38368489 | Leveraging the electronic health record to improve quality and safety in rheumatology. |
| Q35672892 | Linking classification and therapeutic management of vasculitides |
| Q40424259 | Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis |
| Q43416268 | Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. |
| Q87829268 | Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis |
| Q34124668 | Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis |
| Q83978369 | Long-term follow-up of different refractory systemic vasculitides treated with rituximab |
| Q35759180 | Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis |
| Q37682245 | Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis |
| Q38082794 | Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation. |
| Q37093451 | Long-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study |
| Q41605329 | Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis |
| Q35887318 | Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab |
| Q47191744 | Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial |
| Q33395310 | Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study |
| Q33564565 | Lung involvement in childhood onset granulomatosis with polyangiitis |
| Q26998390 | Lupus nephritis: the evolving role of novel therapeutics |
| Q36652819 | Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis |
| Q42290448 | MPO-C-ANCA-associated necrotising and crescentic glomerulonephritis |
| Q36885682 | Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). |
| Q45752892 | Maintenance of clinical remission in ANCA-associated vasculitis |
| Q38327634 | Maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: who needs what and for how long? |
| Q38818682 | Management of Small Vessel Vasculitides |
| Q42706595 | Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial. |
| Q43236554 | Microscopic polyangiitis causing diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. |
| Q41208166 | Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab? |
| Q37018285 | Molecular diagnosis: Implications for ophthalmology. |
| Q64244469 | Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis |
| Q58621572 | Moving towards new treatments for vasculitis |
| Q91648709 | Multiple pulmonary nodules in granulomatous polyangiitis: A case series |
| Q42122199 | Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis |
| Q26864381 | Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging |
| Q94673520 | Narrative Review of Hypercoagulability in Small-Vessel Vasculitis |
| Q41729275 | Necrotizing RPGN with linear anti IgG deposits in a patient with history of granulomatosis with polyangiitis: a case report |
| Q93052257 | Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab |
| Q37947157 | New indications for biological therapies. |
| Q37820047 | New pathophysiological insights and treatment of ANCA-associated vasculitis |
| Q38135271 | New-generation therapy for ANCA-associated vasculitis |
| Q90529437 | No overlap between IgG4-related disease and microscopic polyangiitis and granulomatosis with polyangiitis despite elevated serum IgG4 at diagnosis: a retrospective monocentric study |
| Q37118955 | Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. |
| Q39367854 | Off-label use of rituximab for systemic lupus erythematosus in Europe |
| Q92211308 | Oral candidiasis is a significant predictor of subsequent severe infections during immunosuppressive therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q41428133 | Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids |
| Q36508873 | Outcomes of patients admitted to intensive care units for acute manifestation of small-vessel vasculitis: a multicenter, retrospective study |
| Q38104641 | Overview of vasculitis and vasculopathy in rheumatoid arthritis--something to think about |
| Q39072021 | Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. |
| Q38946711 | Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. |
| Q58567390 | Pathogenesis of ANCA-Associated Pulmonary Vasculitis |
| Q37845187 | Pathogenesis of ANCA-associated vasculitis, an update |
| Q40594099 | Pathogenesis of antimicrobial peptides LL-37 and CpG-ODN in ANCA associated vasculitis |
| Q28383761 | Pathophysiology of ANCA-Associated Small Vessel Vasculitis |
| Q47619266 | Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. |
| Q37739037 | Patients with ANCA-associated vasculitis admitted to the intensive care unit with acute vasculitis manifestations: a retrospective and comparative multicentric study |
| Q36199241 | Pauci-Immune Necrotizing and Crescentic Glomerulonephritis with Membranous Lupus Nephritis, Fifteen Years after Initial Diagnosis of Secondary Membranous Nephropathy |
| Q36304029 | Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage. |
| Q37031689 | Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis |
| Q89694411 | Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis |
| Q36715376 | Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial |
| Q34708735 | Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis |
| Q38794907 | Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? |
| Q53217275 | Poor renal outcomes in patients with anti-neutrophil cytoplasmic antibody-associated crescentic glomerulonephritis and normal renal function at diagnosis. |
| Q35043103 | Practice patterns of ANCA-associated vasculitis: exploring differences among subspecialties at a single academic medical centre |
| Q40657767 | Predictive factors for mortality in elderly Japanese patients with severe microscopic polyangiitis: A retrospective single-center study. |
| Q33571802 | Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure |
| Q38154934 | Preliminary analysis of mortality associated with rituximab use in autoimmune diseases |
| Q58773547 | Primary Vasculitis in Childhood: GPA and MPA in Childhood |
| Q35777619 | Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? |
| Q41746643 | Prognosis and therapy of inflammatory rheumatic diseases : Impact of renal manifestations |
| Q38155072 | Progress in peripheral nerve disease research in the last two years |
| Q21195258 | Progress in treatment of ANCA-associated vasculitis |
| Q38389307 | Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus |
| Q36152477 | Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). |
| Q39770818 | Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis |
| Q36104863 | Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis |
| Q27008053 | Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature |
| Q49679461 | Pyoderma Gangrenosum-associated Granulomatosis with Polyangitis: A Case Report and Literature Review |
| Q46609151 | Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis |
| Q35617617 | Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label |
| Q26751357 | Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q26747046 | Recent advances in understanding and treating vasculitis |
| Q64980226 | Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. |
| Q37879814 | Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. |
| Q50850119 | Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease |
| Q85921570 | Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies |
| Q57945954 | References |
| Q42342710 | Refractory rheumatoid vasculitis-a therapeutic dilemma |
| Q92544359 | Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis |
| Q47134404 | Relapsing granulomatosis with polyangiitis with severe lung and upper respiratory tract involvement successfully treated with rituximab. |
| Q30704972 | Remission induction in ANCA-associated vasculitis: Follow-up data of the RAVE study |
| Q38260987 | Renal transplantation in anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Q50991407 | Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions |
| Q38149916 | Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions |
| Q38204971 | Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? |
| Q38534478 | Rheumatologic emergencies |
| Q36538948 | Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving Rituximab |
| Q55440952 | Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. |
| Q33757203 | Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab |
| Q84617794 | Rituximab Treatment for Vasculitis |
| Q27021256 | Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome |
| Q38576072 | Rituximab as an alternative for patients with severe systemic vasculitis refractory to conventional therapy: report of seven cases and literature review |
| Q35662018 | Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. |
| Q38100232 | Rituximab biosimilars |
| Q43837591 | Rituximab for ANCA-associated vasculitis in the setting of severe infection |
| Q42239031 | Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients |
| Q34687563 | Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation |
| Q38051300 | Rituximab for refractory granulomatous eye disease |
| Q47581564 | Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center |
| Q37556428 | Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus |
| Q35890027 | Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. |
| Q46074717 | Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant |
| Q46117432 | Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. |
| Q35557092 | Rituximab for the treatment of Churg-Strauss syndrome with renal involvement |
| Q41622904 | Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). |
| Q40927033 | Rituximab for treatment of severe renal disease in ANCA associated vasculitis |
| Q84859294 | Rituximab in AAV: when and how to use it |
| Q39117005 | Rituximab in ANCA-Associated Vasculitis |
| Q28076091 | Rituximab in autoimmune diseases |
| Q34573847 | Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal |
| Q37989298 | Rituximab in immunologic glomerular diseases |
| Q37859111 | Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis |
| Q64055590 | Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series |
| Q39305650 | Rituximab in severe, treatment-refractory interstitial lung disease. |
| Q48113733 | Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener's). |
| Q82482682 | Rituximab or Cyclophosphamide in ANCA-Associated Renal Vasculitis |
| Q38905969 | Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature |
| Q35064588 | Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial |
| Q41667048 | Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters |
| Q37686029 | Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. |
| Q35109118 | Rituximab versus cyclophosphamide for ANCA-associated vasculitis |
| Q35228543 | Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement |
| Q33802001 | Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. |
| Q41450353 | Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial |
| Q88020335 | Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis |
| Q38033648 | Rituximab: emerging treatment strategies of immune-mediated glomerular disease |
| Q50076914 | S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis |
| Q35557832 | Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). |
| Q36394613 | Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2) |
| Q38284560 | Safety of off-label biologicals in systemic lupus erythematosus |
| Q55286318 | Severe localised granulomatosis with polyangiitis (Wegener's granulomatosis) manifesting with extensive cranial nerve palsies and cranial diabetes insipidus: a case report and literature review. |
| Q38113507 | Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? |
| Q42380186 | Should rituximab be used to prevent relapse in patients with ANCA-associated vasculitis? |
| Q41758285 | Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients |
| Q26776308 | Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives |
| Q41126772 | Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis. |
| Q38263514 | State of the art in the treatment of systemic vasculitides |
| Q35071121 | Successful induction of granulomatosis with polyangiitis with tacrolimus. |
| Q55252798 | Successful reconstruction of an ocular defect resulting from granulomatosis with polyangiitis, following treatment with rituximab. |
| Q51201626 | Successful treatment of Takayasu arteritis with rituximab as a first-line immunosuppressant |
| Q49887883 | Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis |
| Q35614757 | Successful use of Rituximab in a patient with recalcitrant multisystemic eosinophilic granulomatosis with polyangiitis |
| Q90290630 | Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders |
| Q47163408 | Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomen |
| Q64238813 | Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes |
| Q34171890 | T cell-macrophage interactions and granuloma formation in vasculitis. |
| Q92435113 | T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach |
| Q37814530 | Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? |
| Q33620537 | Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond |
| Q41592598 | The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study. |
| Q47107377 | The European Vasculitis Society 2016 Meeting Report |
| Q36820858 | The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. |
| Q26740453 | The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China |
| Q26740451 | The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries |
| Q42399755 | The Search for a Biomarker of Relapse in ANCA-Associated Vasculitis |
| Q34345029 | The downsides of a major medical advance |
| Q33683956 | The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease |
| Q39266532 | The nonsystemic vasculitic neuropathies |
| Q47857626 | The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice |
| Q38017164 | The pulmonary vasculitides |
| Q37950904 | The role of biologics in treatment of ANCA-associated vasculitis |
| Q90117071 | The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis |
| Q59160663 | Therapeutic Management of Pediatric Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis |
| Q26750499 | Therapeutic advances in the treatment of vasculitis |
| Q38965278 | Therapy and prognosis of ANCA-associated vasculitis from the clinical nephrologist's perspective. |
| Q85163178 | Therapy: Rituximab has similar short-term safety and efficacy to cyclophosphamide in ANCA-associated vasculitis |
| Q48152186 | Toothache and hearing loss: early symptoms of granulomatosis with polyangiitis (GPA). |
| Q50089937 | Towards precision medicine in ANCA-associated vasculitis |
| Q42362479 | Treating elderly patients with ANCA-associated vasculitis |
| Q38016380 | Treatment of ANCA-associated vasculitis, where to go? |
| Q38159916 | Treatment of ANCA-associated vasculitis. |
| Q88687918 | Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review |
| Q38341601 | Treatment of granulomatosis with polyangiitis (Wegener's). |
| Q39410091 | Treatment of membranous nephropathy: time for a paradigm shift |
| Q37912214 | Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? |
| Q38135684 | Treatment of primary systemic necrotizing vasculitides: the role of biotherapies |
| Q30486655 | Treatment of renal manifestations of ANCA-associated vasculitis |
| Q38219932 | Treatment of severe and/or refractory ANCA-associated vasculitis |
| Q41192540 | Treatment strategies for ANCA-associated vasculitides |
| Q37037298 | Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease |
| Q89293824 | Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis |
| Q38389839 | Twenty-five years of European Union collaboration in ANCA-associated vasculitis research |
| Q26991813 | Understanding the role of B cells in atherosclerosis: potential clinical implications |
| Q42563782 | Understanding the role of rituximab in ANCA GN: regressing toward the mean |
| Q48592090 | Unmet Needs in the Pathogenesis and Treatment of Vasculitides. |
| Q37851001 | Unresolved issues in biologic therapy for rheumatoid arthritis |
| Q36354929 | Update on diffuse alveolar hemorrhage and pulmonary vasculitis |
| Q37970443 | Update on the role of rituximab in kidney diseases and transplant |
| Q83308499 | Update on the treatment of granulomatosis with polyangiitis (Wegener's) |
| Q28069897 | Updates in ANCA-associated vasculitis |
| Q58711212 | Use of rituximab as an induction therapy in anti-glomerular basement-membrane disease |
| Q35007874 | Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome |
| Q37338909 | Variability in experts' opinions regarding risks and treatment choices in patients with antineutrophil cytoplasmic antibody-associated vasculitis |
| Q34538062 | Variability of the impact of adverse events on physicians' decision making |
| Q39215583 | Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the US. |
| Q56882317 | Vasculitic neuropathies |
| Q39379384 | Vasculitis for the internist: focus on ANCA-associated vasculitis |
| Q86067600 | Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis? |
| Q91741001 | Vasculitis: A Checklist to Approach and Treatment Update for Dermatologists |
| Q83667540 | Vasculitis: Risks and rewards of treating elderly patients with vasculitis |
| Q82971926 | Vasculitis: Rituximab: effective in ANCA-associated vasculitis? |
| Q83396580 | Vasculitis: the elusive optimal induction strategy for vasculitis |
| Q93074085 | WITHDRAWN: [Treatment of ANCA-associated vasculitides: Certainties and controversies] |
| Q53060772 | What are the Newer Applications for Therapeutic Apheresis in Nephrology?: Clinical Application of Therapeutic Apheresis in Nephrology in Japan. |
| Q28259540 | What is new in the management of rapidly progressive glomerulonephritis? |
| Q52863617 | [Adult onset Still's disease with small vessel vasculitis]. |
| Q90677803 | [A rare manifestation of an inflammatory rheumatic systemic disease] |
| Q84757151 | [Classification and therapy of vasculitis according to recommendations of the European League Against Rheumatism (EULAR)] |
| Q88930851 | [De-escalation of therapy in ANCA-associated vasculitides] |
| Q84584210 | [Development of morbidity and mortality in ANCA-associated vasculitis] |
| Q85714424 | [Personalized medicine in the choice of conventional immunosuppressants and disease modifying antirheumatic drugs] |
| Q84378951 | [Pulmonary emergencies in connective tissues disorders and vasculitides] |
| Q89110022 | [Recommendations on the use of rituximab for ANCA-associated vasculitis] |
| Q84378946 | [Renal emergencies in cases of collagenosis and vasculitis] |
| Q84806400 | [Rheumatic diseases with initial manifestations in middle age: gout, rheumatoid arthritis and ANCA-associated vasculitides] |
| Q83932089 | [Therapy of vasculitides: according to recommendations of the European League Against Rheumatism (EULAR) and European Vasculitis Study Group (EUVAS)] |
| Q85397945 | [Update on granulomatosis with polyangitis (GPA, Wegener's granulomatosis)] |
| Q89017278 | [What rheumatologists can learn from nephrologists] |
| Q57053858 | antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes |
Search more.